On CNBC's Fast Money, Jon Najarian said that The Goodyear Tire & Rubber Company (NASDAQ: GT) had unusual activity several times in the last 20 days and it spiked more than 5 percent on Wednesday. He had a long position in the stock and he took profits at $24.
Mike Murphy thinks that Panera Bread Co (NASDAQ: PNRA) didn't post a great report, but it is possible to find some positives in it as same-store sales increased by more than 3 percent. He doesn't like the company from the fundamental stand point but the chart looks good to him. Murphy thinks that $160 price level should hold. Panera Bread Co traded 4.47 percent lower.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
Josh Brown commented on Hershey Co's (NYSE: HSY) 2 percent decline. He wouldn't buy the dip because the company's earnings showed weaker global sales. The company is struggling because of higher dairy prices and stronger dollar. The dividend yield is not attractive enough for the staples space and the chart looks terrible, thinks Brown. He would avoid this stock.
Gilead Sciences, Inc. (NASDAQ: GILD) managed to beat estimates on Tuesday despite lower sales of its hepatitis C drug. Stephen Weiss thinks that this shows that it is not just a hepatitis C company. He has a long position but he doesn't have any more room to add on a dip of 2.26 percent. Weiss believes that the story is going to get just better.